TAIPEI (Taiwan News) — Gongwin Biopharm Holdings Co.’s new animal cancer drug has received marketing approval from the Ministry of Agriculture to treat melanoma in dogs, Liberty Times reported Saturday.
Melanoma develops from pigment-producing cells and is one of the most common cancers in dogs. It can occur on the skin, toes, and in the mouth, with oral melanoma accounting for more than 80% of cases and being particularly aggressive, according to SBM.
Gongwin’s Gwa103 uses a mechanism called intratumoral drug ablation to destroy cancer cells. The drug selectively enters malignant cells, helping reduce damage to surrounding healthy tissue, according to Anue.
Current treatment relies mainly on surgery and chemotherapy. Because canine melanoma often develops in the mouth and limbs and can affect large areas, surgery may require the removal of additional tissue.
Gongwin has signed letters of intent to collaborate on the drug with more than 100 animal hospitals across Taiwan. The drug can be used as a standalone treatment or in combination with other cancer therapies, according to UDN Money.
After completing labeling, supply chain arrangements, and hospital onboarding, the company plans to begin supplying the drug in stages in accordance with regulatory requirements. It will also provide clinical training for veterinary teams.
Gwa103 is also eligible for conditional marketing approval in the US, where Gongwin has obtained authorization to conduct clinical trials. The company also plans to expand into other major pet markets, including Australia, Japan, China, and Hong Kong.
Fortune Business Insights said the global veterinary oncology market was worth NT$91.9 billion (US$2.9 billion) in 2025. It estimates the market will grow at a compound annual growth rate of 10.7% from 2026 to reach NT$225 billion by 2034.
